A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Public ClinicalTrials.gov record NCT00739648. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to Prevent Acute Exacerbations in High Risk COPD Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an increased risk of death, a decline in pulmonary function and a significant change in quality of life. Bacteria appear to have an important role in acute exacerbations in chronic bronchitis and COPD. Studies of acute exacerbations in COPD have shown a reduction in bacterial load with prolonged exacerbation-free interval. In addition, recent studies indicate that acquisition of a new strain of H. influenzae, M. catarrhalis, S. pneumoniae or P. aeruginosa are responsible for many of these exacerbations. Chronic inflammation and bacterial infection predispose many patients to frequent and recurrent acute exacerbations. Mpex believes that intermittent administration of inhaled MP-376 in high risk patients will decrease the incidence of acute exacerbations by both by lowering the organism burden, and resultant inflammation, as well as pre-emptive eradication of any newly acquired bacterial strains.
Study identification
- NCT ID
- NCT00739648
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 322 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2008 (Type not available)
- Primary completion
- Jan 2010 (Actual)
- Completion
- Apr 2010 (Actual)
- Last update posted
- Dec 27, 2024
2008 – 2010
United States locations
- U.S. sites
- 39
- U.S. states
- 17
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Haleyville | Alabama | 35565 | — |
| Not listed | Hueytown | Alabama | 35023 | — |
| Not listed | Mobile | Alabama | 36608 | — |
| Not listed | Montgomery | Alabama | 36117 | — |
| Not listed | Glendale | Arizona | 85306 | — |
| Not listed | Phoenix | Arizona | 85006 | — |
| Not listed | Chula Vista | California | 91911 | — |
| Not listed | Lomita | California | 90717 | — |
| Not listed | Long Beach | California | 90822 | — |
| Not listed | Mission Viejo | California | 92691 | — |
| Not listed | Oceanside | California | 92056 | — |
| Not listed | Palo Alto | California | 94304 | — |
| Not listed | Riverside | California | 92506 | — |
| Not listed | San Diego | California | 92117 | — |
| Not listed | San Jose | California | 95124 | — |
| Not listed | Wheat Ridge | Colorado | 80033 | — |
| Not listed | Clearwater | Florida | 33765 | — |
| Not listed | DeBary | Florida | 32713 | — |
| Not listed | DeLand | Florida | 32720 | — |
| Not listed | Orlando | Florida | 32806 | — |
| Not listed | Savannah | Georgia | 31406 | — |
| Not listed | New Orleans | Louisiana | 70115 | — |
| Not listed | Taylor | Michigan | 48180 | — |
| Not listed | Omaha | Nebraska | 68198 | — |
| Not listed | Buffalo | New York | 14215 | — |
| Not listed | Ithaca | New York | 14850 | — |
| Not listed | Greenville | North Carolina | 27834 | — |
| Not listed | Columbus | Ohio | 43210 | — |
| Not listed | Maumee | Ohio | 43537 | — |
| Not listed | Toledo | Ohio | 43614 | — |
| Not listed | Medford | Oregon | 97504 | — |
| Not listed | Johnston | Rhode Island | 02919 | — |
| Not listed | Easley | South Carolina | 29640 | — |
| Not listed | Gaffney | South Carolina | 29340 | — |
| Not listed | Spartanburg | South Carolina | 29303 | — |
| Not listed | Union | South Carolina | 29379 | — |
| Not listed | San Antonio | Texas | 78212 | — |
| Not listed | Richmond | Virginia | 23225 | — |
| Not listed | Salem | Virginia | 24153 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00739648, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 27, 2024 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00739648 live on ClinicalTrials.gov.